id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-N-0832-0062,FDA,FDA-2016-N-0832,Second Joint Status Report re Carbadox,Other,Report,2018-12-21T05:00:00Z,2018,12,2018-12-21T05:00:00Z,,2018-12-21T15:02:23Z,,0,0,09000064839bea66
FDA-2016-N-0832-0061,FDA,FDA-2016-N-0832,Joint Status Report 1 Final 8-31-18,Other,Report,2018-08-31T04:00:00Z,2018,8,2018-08-31T04:00:00Z,,2018-08-31T13:28:59Z,,0,0,090000648368487d
FDA-2016-N-0832-0060,FDA,FDA-2016-N-0832,Carbadox Letter March 30 18,Other,Letter(s),2018-04-02T04:00:00Z,2018,4,2018-04-02T04:00:00Z,,2018-04-02T13:27:35Z,,0,0,0900006483085912
FDA-2016-N-0832-0059,FDA,FDA-2016-N-0832,Letter from Covington to FDA,Other,Letter(s),2018-03-30T04:00:00Z,2018,3,2018-03-30T04:00:00Z,,2018-03-30T16:34:05Z,,0,0,090000648307537a
FDA-2016-N-0832-0058,FDA,FDA-2016-N-0832,"Legal and FDA Reference Material: Letter, CVM Request to Director Warren 3-16-18",Other,Request for Extension,2018-03-21T04:00:00Z,2018,3,,,2018-04-03T13:45:07Z,,0,0,090000648302a2a0